The Future of R&D Outsourcing
Investigating development hurdles, key challenges & strategies to optimize CRO relationships

By Alison Sahoo
Alison Sahoo

Alison Sahoo is a pharmaceutical industry analyst with more than 10 years of experience researching the development of medicines and medical devices. She holds a B.S. in Physics from McGill University and an MBA in International Business from Rutgers University.
Table of Contents

The Future of R&D Outsourcing

Challenges facing drug developers 10
Dynamics of outsourced R&D 11
R&D outsourcing in Asia 12
Strategies to optimize R&D outsourcing relationships 13
The future of R&D outsourcing 14

Chapter 1 Challenges facing drug developers 16

Summary 16
The drug approval process 17
US 17
Europe 21
The Mutual Recognition Procedure (MRP) 21
The National Competent Authorities 23
Rising financial pressure 24
Expiring patents on blockbusters 24
Decreasing market exclusivity 27
Healthcare cost containment 28
Rising usage of generics 28
Elimination of coverage 30
Step therapy 31
Utilization of OTCs 31
Manufacturer rebates 32
Consumer skepticism of drug benefits 32
Drug development imperatives 33
Targeting large markets 34
Focus on efficacy 34
Expansion into biologicals 36
Decreasing time to market 36
Drug development hurdles 37
More complicated disease targets 38
Rapidly escalating costs 38
Reduced R&D staff 40
Heightened regulatory scrutiny 43
Declining drug approvals 44
Conclusion 46
Chapter 2  Dynamics of outsourced R&D  50

Summary  50

Contract research organizations  51
The role of CROs  51
Services offered by CROs  51
  Discovery  53
  Preclinical evaluation  54
  Clinical trials  54
  Repositioning  55
Expanding technological expertise  56

Reasons for outsourcing R&D  56
Types of relationships  60
Preferred vendors  63
Functional service providers  64
Risk sharing  64
Technology partnerships  65
Drug licensing  66

Benefits and limitations of using CROs  66
Long term cost savings vs. high short term expenses  67
Speed to market vs. potential project overruns  68
Access to expertise vs. CRO staff turnover  70
Flexibility vs. loss of control  71
Ability to customize research vs. CRO clutter  72

CRO usage  72
Usage estimates 2009 - 2014  73
Leading CROs  73
Conclusion  74

Chapter 3  R&D outsourcing in Asia  78

Summary  78

Introduction  79
Offshore outsourcing of clinical research  81
Offshore outsourcing of preclinical research  82

Contract research in India  84
Key outsourcing issues  86
  Intellectual property  86
  Regulatory issues  87
  Business issues and infrastructure  88
Leading players  90
  CRO usage and market size  90
  CRO developments in India  91
  Case study: GlaxoSmithKline  92

Contract research in China  95
List of Figures

Figure 1.1: US and EU spending on generic drugs, 2009 30
Figure 1.2: US NME approvals vs. R&D spend ($bn), 1990-2009* 46
Figure 1.3: Average US R&D spend per NME approval ($m), 1990 – 2009* 47
Figure 2.4: Services offered by CROs 52
Figure 2.5: Potential benefits and limitations of using a CRO 68
Figure 2.6: Growth of outsourced R&D by segment ($m), 2009-14 74
Figure 2.7: Market analysis of major CROs, 2009 75
Figure 3.8: Advantages and disadvantages of leading Asian outsourcing venues 80
Figure 3.9: Clinical and preclinical test capabilities of India and China 83
Figure 3.10: Growth of outsourced R&D to India by segment, 2009-14 91
Figure 3.11: GlaxoSmithKline sales vs. R&D expense (£m), 2000-09 94
Figure 3.12: Growth of outsourced R&D to China by segment ($m), 2009-14 104
Figure 3.13: Eli Lilly sales vs. R&D expense ($m), 2000-09 107
Figure 3.14: Key characteristics of offshore partnering relationships 109
Figure 4.15: Risk factors when outsourcing R&D 117
Figure 5.16: Confidence level of drug development & outsourcing predictions, near vs. long term 143
Figure 5.17: Drug development trends, near vs. long term 144
Figure 5.18: Relative usage & growth of different types of R&D outsourcing relationships, near vs. long term 148
Figure 5.19: R&D outsourcing trends, near vs. long term 151

List of Tables

Table 1.1: CDER Drug Advisory Committees, December 2009 21
Table 1.2: Leading European National Competent Authorities, 2009 25
Table 1.3: Leading European National Competent Authorities, 2009 (ctd) 26
Table 1.4: Revenues and patent expirations for selected companies’ blockbusters, 2009 27
Table 1.5: Leading medicinal research areas, 2009 35
Table 1.6: Significant R&D staff reductions, 2008-09 41
<table>
<thead>
<tr>
<th>Table 1.7:</th>
<th>US NME approvals, 2000-09</th>
<th>45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1.8:</td>
<td>US R&amp;D spend for approved NMEs ($), 1990-2009</td>
<td>45</td>
</tr>
<tr>
<td>Table 2.9:</td>
<td>Key characteristics of CRO partnering relationships</td>
<td>62</td>
</tr>
<tr>
<td>Table 4.10:</td>
<td>Reasons for time and budget overruns</td>
<td>127</td>
</tr>
<tr>
<td>Table 4.11:</td>
<td>Corporate cultural characteristics of sponsors and contractors</td>
<td>129</td>
</tr>
<tr>
<td>Table 5.12:</td>
<td>Global growth of outsourced R&amp;D by stage ($bn), 2009-14</td>
<td>153</td>
</tr>
</tbody>
</table>